AIM ImmunoTech Net Income
| AIM Stock | USD 0.88 0.10 10.46% |
As of the 11th of February 2026, AIM ImmunoTech shows the Coefficient Of Variation of (784.73), mean deviation of 4.34, and Risk Adjusted Performance of (0.09). AIM ImmunoTech technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm AIM ImmunoTech standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and kurtosis to decide if AIM ImmunoTech is priced adequately, providing market reflects its regular price of 0.8775 per share. Given that AIM ImmunoTech is a hitting penny stock territory we recommend to closely look at its jensen alpha.
AIM ImmunoTech Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 27.9031 | Revenue | Earnings Share (18.26) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -15.6 M | -16.4 M | |
| Net Loss | -15.6 M | -16.4 M | |
| Net Loss | -19.9 M | -20.9 M | |
| Net Loss | (27.83) | (29.22) | |
| Net Income Per E B T | 1.12 | 1.08 |
AIM | Net Income | Build AI portfolio with AIM Stock |
Evaluating AIM ImmunoTech's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into AIM ImmunoTech's fundamental strength.
Latest AIM ImmunoTech's Net Income Growth Pattern
Below is the plot of the Net Income of AIM ImmunoTech over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in AIM ImmunoTech financial statement analysis. It represents the amount of money remaining after all of AIM ImmunoTech operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is AIM ImmunoTech's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AIM ImmunoTech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (17.32 M) | 10 Years Trend |
|
Net Income |
| Timeline |
AIM Net Income Regression Statistics
| Arithmetic Mean | (14,309,494) | |
| Coefficient Of Variation | (43.31) | |
| Mean Deviation | 4,713,408 | |
| Median | (15,588,000) | |
| Standard Deviation | 6,197,877 | |
| Sample Variance | 38.4T | |
| Range | 27.2M | |
| R-Value | (0.52) | |
| Mean Square Error | 29.9T | |
| R-Squared | 0.27 | |
| Significance | 0.03 | |
| Slope | (638,831) | |
| Total Sum of Squares | 614.6T |
AIM Net Income History
Other Fundumenentals of AIM ImmunoTech
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
AIM ImmunoTech Net Income component correlations
AIM Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for AIM ImmunoTech is extremely important. It helps to project a fair market value of AIM Stock properly, considering its historical fundamentals such as Net Income. Since AIM ImmunoTech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AIM ImmunoTech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AIM ImmunoTech's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could AIM diversify its offerings? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AIM ImmunoTech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (18.26) | Revenue Per Share | Quarterly Revenue Growth (0.26) | Return On Assets | Return On Equity |
AIM ImmunoTech's market price often diverges from its book value, the accounting figure shown on AIM's balance sheet. Smart investors calculate AIM ImmunoTech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since AIM ImmunoTech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that AIM ImmunoTech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AIM ImmunoTech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
AIM ImmunoTech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to AIM ImmunoTech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of AIM ImmunoTech.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in AIM ImmunoTech on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding AIM ImmunoTech or generate 0.0% return on investment in AIM ImmunoTech over 90 days. AIM ImmunoTech is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple... More
AIM ImmunoTech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure AIM ImmunoTech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess AIM ImmunoTech upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 32.69 | |||
| Value At Risk | (10.32) | |||
| Potential Upside | 7.69 |
AIM ImmunoTech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for AIM ImmunoTech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as AIM ImmunoTech's standard deviation. In reality, there are many statistical measures that can use AIM ImmunoTech historical prices to predict the future AIM ImmunoTech's volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.86) | |||
| Total Risk Alpha | (1.35) | |||
| Treynor Ratio | (0.58) |
AIM ImmunoTech February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.57) | |||
| Mean Deviation | 4.34 | |||
| Coefficient Of Variation | (784.73) | |||
| Standard Deviation | 5.83 | |||
| Variance | 33.94 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.86) | |||
| Total Risk Alpha | (1.35) | |||
| Treynor Ratio | (0.58) | |||
| Maximum Drawdown | 32.69 | |||
| Value At Risk | (10.32) | |||
| Potential Upside | 7.69 | |||
| Skewness | 0.5092 | |||
| Kurtosis | 1.51 |
AIM ImmunoTech Backtested Returns
AIM ImmunoTech secures Sharpe Ratio (or Efficiency) of -0.11, which signifies that the company had a -0.11 % return per unit of return volatility over the last 3 months. AIM ImmunoTech exposes twenty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm AIM ImmunoTech's Coefficient Of Variation of (784.73), risk adjusted performance of (0.09), and Mean Deviation of 4.34 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.31, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, AIM ImmunoTech will likely underperform. At this point, AIM ImmunoTech has a negative expected return of -0.65%. Please make sure to confirm AIM ImmunoTech's total risk alpha, as well as the relationship between the kurtosis and price action indicator , to decide if AIM ImmunoTech performance from the past will be repeated in the future.
Auto-correlation | 0.46 |
Average predictability
AIM ImmunoTech has average predictability. Overlapping area represents the amount of predictability between AIM ImmunoTech time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of AIM ImmunoTech price movement. The serial correlation of 0.46 indicates that about 46.0% of current AIM ImmunoTech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.46 | |
| Spearman Rank Test | 0.29 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
AIM Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, AIM ImmunoTech reported net income of (17.32 Million). This is 105.07% lower than that of the Biotechnology sector and 124.73% lower than that of the Health Care industry. The net income for all United States stocks is 103.03% higher than that of the company.
AIM Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AIM ImmunoTech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AIM ImmunoTech could also be used in its relative valuation, which is a method of valuing AIM ImmunoTech by comparing valuation metrics of similar companies.AIM ImmunoTech is currently under evaluation in net income category among its peers.
AIM Fundamentals
| Return On Equity | -31.39 | ||||
| Return On Asset | -0.95 | ||||
| Operating Margin | (94.12) % | ||||
| Current Valuation | 3.13 M | ||||
| Shares Outstanding | 3.28 M | ||||
| Shares Owned By Insiders | 3.85 % | ||||
| Shares Owned By Institutions | 4.98 % | ||||
| Number Of Shares Shorted | 61.95 K | ||||
| Price To Earning | 12.50 X | ||||
| Price To Book | 2.72 X | ||||
| Price To Sales | 28.54 X | ||||
| Revenue | 170 K | ||||
| Gross Profit | 17 K | ||||
| EBITDA | (16.49 M) | ||||
| Net Income | (17.32 M) | ||||
| Cash And Equivalents | 1.7 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 2.94 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.21 X | ||||
| Book Value Per Share | (2.20) X | ||||
| Cash Flow From Operations | (14.89 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (18.26) X | ||||
| Price To Earnings To Growth | (0.04) X | ||||
| Target Price | 13.99 | ||||
| Number Of Employees | 21 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 3.2 M | ||||
| Total Asset | 8.61 M | ||||
| Retained Earnings | (426.83 M) | ||||
| Working Capital | (5.36 M) | ||||
| Current Asset | 15.73 M | ||||
| Current Liabilities | 6.65 M | ||||
| Net Asset | 8.61 M |
About AIM ImmunoTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AIM ImmunoTech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AIM ImmunoTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AIM ImmunoTech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Will Biotechnology sector continue expanding? Could AIM diversify its offerings? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AIM ImmunoTech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (18.26) | Revenue Per Share | Quarterly Revenue Growth (0.26) | Return On Assets | Return On Equity |
AIM ImmunoTech's market price often diverges from its book value, the accounting figure shown on AIM's balance sheet. Smart investors calculate AIM ImmunoTech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since AIM ImmunoTech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that AIM ImmunoTech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AIM ImmunoTech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.